Conduct of interest
Not declared by any author.

Funding source
This study was supported, in part, by the ‘Progetto Ricerca Corrente – R.C. 4.3 2020’ of the Italian Ministry of Health, Rome, Italy.

F. Ricci,1,* L. Fania,1 X A. Paradisi,2 X G. Di Lella,1 S. Pallotta,1 L. Sobrino,1 A. Panebianco,1 G. Annessi,1 D. Abeni1

1IDI-IRCCS, Rome, Italy, 2Cristo Re’ General Hospital, Rome, Italy
*Correspondence: F. Ricci. E-mail: fraric1984@libero.it

References
1 Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol 2018; 25: 2105–2110.
2 Esserman LJ, Thompson IM, Jr, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA 2013; 310: 797–798.
3 Sacchetto L, Zanetti R, Comber H et al. Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer 2018; 92: 108–118.
4 Ferris LK, Saul MJ, Lin Y et al. A large skin cancer screening quality initiative: description and first-year outcomes. JAMA Oncol 2017; 3: 1112–1115.
5 Gomolin T, Cline A, Handler MZ. The danger of neglecting melanoma during the COVID-19 pandemic. Dermatolog Treat 2020; 31: 444–445.
6 Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health. URL www.OpenEpi.com, updated 2013/04/06, (last accessed: 15 June 2020).

COVID-19-related cutaneous manifestations associated with multiple drug sensitization as shown by lymphocyte transformation test

Editor
Patients with novel coronavirus disease 2019 (COVID-19) can present with a wide variety of cutaneous manifestations.1,2
Drug-induced eruptions, however, are often indistinguishable from the COVID-19-related rash. Because many patients (~20%) with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been shown to develop cutaneous manifestations,3 the rash may have been reported as COVID-19-related rash without excluding the possibility of drug eruptions. Here, we report a case suspected of COVID-19-related rash, in which lymphocyte transformation tests (LTTs) to the culprit drugs were positive.

A 44-year-old man presented with fever (38.5°C). He denied cough, sore throat or shortness of breath, and had no history of drug eruptions. On the 17th day of symptoms, he developed erythematous macules and petechiae on his both legs; erythematous macules suddenly appeared in the knee, flexural thigh and popliteal fossae (Fig. 1). Significant laboratory findings are as follows: white blood cell count, 5300/mm³; lymphocyte count, 715/mm³; platelets, 118 000/mm³; and C-reactive protein (CRP), 4.95 mg/dL. CT images displayed ground-glass opacification patterns and bilateral lung involvement. His COVID-19 reverse transcription–polymerase chain reaction test result was positive. About 6 days before the eruption appeared, he had received loxoprofen sodium hydrate, acetaminophen and favipiravir. He recalled that he had used loxoprofen and acetaminophen in the past but only on few occasions. Loxoprofen was withdrawn, and despite the use of acetaminophen and favipiravir, the eruption spontaneously involuted over 4 days without a trace (Fig. 2). LTTs were performed and showed positive reactions to all drugs used. He was discharged 7 days later and has no long-term sequelae.

The main difficulty in assigning a pathogenic role to SARS-CoV-2 infection in any cutaneous manifestation is that there were no or few standard laboratory methods to distinguish between virally induced rash and drug-induced rash. The identification of the causative drug appears to rely on the time interval between the beginning of drug use and onset of rash.4 In our patient, loxoprofen was the most likely causative drug for cutaneous manifestations. In view of our observation that positive LTT reactions were detected not only to loxoprofen but also to
other two drugs (Stimulation Index to each drug, 2.03–2.10), it is likely that our patient was sensitized to all the drugs. Such 'multiple drug hypersensitivity' can be most efficiently proven by LTTs. Interestingly, such 'multiple drug hypersensitivity' was often observed associated with mycoplasma pneumoniae infection. No previous reports, however, described the occurrence of multiple drug hypersensitivity in patients with SARS-CoV-2 infection. A straightforward interpretation is that our patient could be immunologically sensitized to multiple medications probably due to preceding or underlying SARS-CoV-2 infection, although it remains unknown whether SARS-CoV-2 infection could serve to enhance the activation of drug-specific T cells with cross-reactive reactivity. Nevertheless, we cannot totally exclude the possibility that multiple drug sensitization proven solely by LTTs may be a mere epiphenomenon of the underlying SARS-CoV-2 infection.

In conclusion, we recommend that LTT tests be utilized in any patient with cutaneous manifestations of SARS-CoV-2 to exclude the possibility of drug sensitization. Multiple drug hypersensitivity is apparently under-reported because the diagnosis of SARS-CoV-2-induced rash is usually made without performing LTTs. If cutaneous symptoms were viewed as a mere manifestation of SARS-CoV-2 infection with no further search to identify drug hypersensitivity, then the disease would remain regarded as SARS-CoV-2-induced rash. Indeed, the presentation of our patient was consistent with symmetrical drug-related intertriginous and flexural exanthema (SDRIFE). Although SDRIFE-like skin lesions have been reported as a cutaneous manifestation of COVID-19, a drug aetiology could have caused SDRIFE-like skin lesions in patients with SARS-CoV-2 infection.

Acknowledgement
The patient in this manuscript has given written informed consent to publication of his case details.

Conflict of interest
The authors have no conflict of interest to declare.

Funding
The article has no founding source.

J. Hayakawa,1,* H. Takakura,2 Y. Mizukawa,1,3 T. Shiohara1,3
1Division of Dermatology, Kosei Hospital, Tokyo, Japan. 2Division of Respiratory medicine, Kosei Hospital, Tokyo, Japan. 3Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
*Correspondence: J. Hayakawa. E-mail: jun.hayakawa@kosei-hp.or.jp

[Correction added on 14 October 2020, after first online publication: ORCID of authors ‘H.Takahara’ and ‘T.Shiohara’ have been added to this version.]

References
1 Marzano AV, Cassano N, Genovese G, Moltrasio C, Vena GA. Cutaneous manifestations in patients with COVID-19: A preliminary review of an emerging issue. Br J Dermatol 2020; 183: 71–77. https://doi.org/10.1111/bjd.19264
2 Tammaro A, Adebanjo GAR, Parisella FR, Pezzuto A, Rello J. Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome. J Eur Acad Dermatol Venereol 2020; 34: e306–e307. https://doi.org/10.1111/jdv.16530
3 Wollina U, Karadag AS, Rowland-Payne C, Chiriac A, Lotti T. Cutaneous signs in COVID-19 Patients: A review. Dermatol Ther 2020; e13594, 1–6.
4 Mockenhaupt M, Viboud C, Dantas-Torello M, Duquet S, Dubois C, Dugast P, Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The Euro SCSR-study. J Invest Dermatol 2008; 128: 35–44.
5 Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004; 59: 809–820.
6 Aoyama Y, Sawada F, Makino E, Shiohara T. Multiple drug sensitization syndrome: A distinct phenotype associated with unrecognized mycoplasma pneumoniae infection. JAAD Case Rep 2017; 3: 301–305.
7 Takahashi R, Kano Y, Yamazaki Y et al. Defective regulatory T cells in patients with severe drug eruptions: Timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 2009; 182: 8071–8079.
8 Weiss D, Kinaciyan T. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by mafenamic acid. JAAD Case Rep 2019; 5: 89–90.
9 Mahe A, Birckel E, Krieger S, Merklen C, Bottlaender L. A distinctive skin rash associated with Coronavirus Disease 2019? J Eur Acad Dermatol Venereol 2020; 34: e246–e247.

DOI: 10.1111/jdv.16878

Scabies outbreak during home confinement due to the SARS-CoV-2 pandemic

Editor
In response to the rapid spread of COVID-19 at the start of the pandemic, governments introduced severe measures of home confinement and isolation of the population in an effort to prevent their health systems from collapsing. On March 14, with more than 4000 confirmed cases,1 Spain began its nationwide lockdown which has extended for almost three months.

In recent weeks, numerous articles have reported a wide range of skin symptoms of COVID-19,2 but there are other dermatological conditions that may have been aggravated during this global pandemic. Scabies is a highly contagious skin infestation caused by the mite Sarcoptes scabiei (variety hominis). In developed countries, scabies is usually observed sporadically or as institutional outbreaks in hospitals, nursing homes, prisons, long-term care facilities or in displaced persons and asylum seekers.3,4 However, we have observed a significant increase of scabies cases in our region during the confinement period (March, April and May 2020) compared to the average for the same period during the previous five years (64 vs. 18.6 patients).